Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab

IRB16-042
Cancer - Melanoma, Cancer
John McCann, MD

D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. We would also like to find out what effects, good and bad, that this combination of drugs may have on your cancer.
Unresectable Stage III or Stage IV Melanoma
413-794-4154